BIOMAT Database Logo BIOMAT Database Logo

Recovery of the thyroid function in patients with atrophic hypothyroidism and blocking type TSH binding inhibitor immunoglobulin. 1990

K Okamura, and K Sato, and M Yoshinari, and H Ikenoue, and T Kuroda, and M Nakagawa, and H Tsuji, and M Washio, and M Fujishima
Second Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

The prognosis of atrophic hypothyroidism with blocking type TSH-binding inhibitor immunoglobulin was studied. Among 45 patients (16 males and 29 females) with overt hypothyroidism (serum TSH greater than 40 mU/l) without goitre, thyroid autoantibody to microsomal antigen was positive in 38 or 84.4%, and 4 or 8.9% had TSH-binding inhibitor immunoglobulin, which was shown to be a TSH-stimulation blocking antibody by cAMP production assay using cultured porcine thyroid cells. Thyroidal radioactive iodine uptake was low and thyroid hormone replacement therapy was required. Long-term follow up of 2 patients with strongly positive TSH-binding inhibitor immunoglobulin for 2 to 7 years, however, revealed recovery of the thyroid function after steroid therapy or spontaneously with iodide restriction, respectively, correlating with decrease in both TSH-binding inhibitor immunoglobulin and TSH-stimulation blocking antibody activities. Thyroidal radioactive iodine uptake became normal and histological examination of the thyroid in one patient revealed well-preserved thyroid follicles with lymphocytic infiltration. Recovery of thyroid function can be expected with a decrease in TSH-binding inhibitor immunoglobulin activity in atrophic hypothyroidism, which is not necessarily the end stage of chronic thyroiditis.

UI MeSH Term Description Entries
D007037 Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction. Central Hypothyroidism,Primary Hypothyroidism,Secondary Hypothyroidism,TSH Deficiency,Thyroid-Stimulating Hormone Deficiency,Central Hypothyroidisms,Deficiency, TSH,Deficiency, Thyroid-Stimulating Hormone,Hormone Deficiency, Thyroid-Stimulating,Hypothyroidism, Central,Hypothyroidism, Primary,Hypothyroidism, Secondary,Hypothyroidisms,Primary Hypothyroidisms,Secondary Hypothyroidisms,TSH Deficiencies,Thyroid Stimulating Hormone Deficiency,Thyroid-Stimulating Hormone Deficiencies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008928 Mitochondria Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Each mitochondrion is surrounded by a double limiting membrane. The inner membrane is highly invaginated, and its projections are called cristae. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP. They contain distinctive RIBOSOMES, transfer RNAs (RNA, TRANSFER); AMINO ACYL T RNA SYNTHETASES; and elongation and termination factors. Mitochondria depend upon genes within the nucleus of the cells in which they reside for many essential messenger RNAs (RNA, MESSENGER). Mitochondria are believed to have arisen from aerobic bacteria that established a symbiotic relationship with primitive protoeukaryotes. (King & Stansfield, A Dictionary of Genetics, 4th ed) Mitochondrial Contraction,Mitochondrion,Contraction, Mitochondrial,Contractions, Mitochondrial,Mitochondrial Contractions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001284 Atrophy Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes. Atrophies

Related Publications

K Okamura, and K Sato, and M Yoshinari, and H Ikenoue, and T Kuroda, and M Nakagawa, and H Tsuji, and M Washio, and M Fujishima
Histopathological features of atrophic thyroiditis with blocking type-TSH binding inhibitor immunoglobulins.
April 1995, Endocrine journal,
K Okamura, and K Sato, and M Yoshinari, and H Ikenoue, and T Kuroda, and M Nakagawa, and H Tsuji, and M Washio, and M Fujishima
Immunological findings and thyroid function of untreated Graves' disease patients with undetectable TSH-binding inhibitor immunoglobulin.
February 1994, Clinical endocrinology,
K Okamura, and K Sato, and M Yoshinari, and H Ikenoue, and T Kuroda, and M Nakagawa, and H Tsuji, and M Washio, and M Fujishima
Relationship between potency of blocking type thyrotropin-binding inhibitor immunoglobulin in three women with primary myxedema and thyroid function of their neonates.
June 1986, Endocrinologia japonica,
K Okamura, and K Sato, and M Yoshinari, and H Ikenoue, and T Kuroda, and M Nakagawa, and H Tsuji, and M Washio, and M Fujishima
Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
September 1997, Journal of endocrinological investigation,
K Okamura, and K Sato, and M Yoshinari, and H Ikenoue, and T Kuroda, and M Nakagawa, and H Tsuji, and M Washio, and M Fujishima
Scintigraphic findings of the thyroid in hypothyroid patients with blocking-type TSH-receptor antibodies.
September 1994, European journal of nuclear medicine,
K Okamura, and K Sato, and M Yoshinari, and H Ikenoue, and T Kuroda, and M Nakagawa, and H Tsuji, and M Washio, and M Fujishima
[Hypothyroidism due to blocking type anti-TSH receptor antibodies].
January 2000, Ryoikibetsu shokogun shirizu,
K Okamura, and K Sato, and M Yoshinari, and H Ikenoue, and T Kuroda, and M Nakagawa, and H Tsuji, and M Washio, and M Fujishima
[TSH value in children with normal thyroid function and primary hypothyroidism].
January 1976, Godisen zbornik na Medicinskiot fakultet vo Skopje,
K Okamura, and K Sato, and M Yoshinari, and H Ikenoue, and T Kuroda, and M Nakagawa, and H Tsuji, and M Washio, and M Fujishima
Disappearance of blocking type thyrotropin binding inhibitor immunoglobulin (TBII) during thyroid and steroid medication in a patient with autoimmune thyroiditis.
April 1987, Endocrinologia japonica,
K Okamura, and K Sato, and M Yoshinari, and H Ikenoue, and T Kuroda, and M Nakagawa, and H Tsuji, and M Washio, and M Fujishima
Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites.
March 2007, The Journal of clinical endocrinology and metabolism,
K Okamura, and K Sato, and M Yoshinari, and H Ikenoue, and T Kuroda, and M Nakagawa, and H Tsuji, and M Washio, and M Fujishima
Alternating hyper- and hypothyroidism with thyroid-stimulating and TSH-binding inhibition immunoglobulins.
December 1987, Acta paediatrica Japonica : Overseas edition,
Copied contents to your clipboard!